19 June 2025
Over the past two months, we’ve had the privilege of engaging with the healthcare communications and patient engagement communities at MAPS EMEA, ISMPP Annual, ISPOR US and Patients as Partners Europe. Across continents and conversations, one theme clearly stood out: patient involvement is no longer optional – it is essential.
Oxford PharmaGenesis™ will be showcasing its new HealthScience approach to demonstrating product value and achieving market access at ISPOR’s 19th Annual International Meeting in Montreal, Canada (31 May–4 June 2014).
Oxford PharmaGenesis Value Demonstration Practice is proud to be an exhibitor once again at this year’s ISPOR International Meeting in Montreal, Canada.
Leading independent consultancy Oxford PharmaGenesis is pioneering the innovative discipline of HealthScience. For the first time, this integrates the clinical and scientific dimensions of healthcare with the economic, social, behavioural and political perspectives that determine the value of new medicines and health interventions.
Addressing heart failure must be considered a global health priority because poor awareness of the disease leads to many premature deaths. Approximately 26 million people are living with heart failure worldwide, and if current trends continue the disease will impose ever-increasing burdens on patients, caregivers and healthcare systems.
Recent announcements regarding Government investments in Oxfordshire are good news for those working within biosciences in the county.
